Genes involved in BCR signaling and B‐cell activation (MYD88, CARD11, TBL1XR1, CD79B, TNFAIP3) or epigenetic regulators (KMT2D, CREBBP, TET2) were observed at frequencies comparable with de novo DLBCL subtypes. Here, CREBBP is linked to diffuse large B-cell lymphoma.